Miguel A. Torralba

Toledo, CM, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 24, 2026

Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV.

Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV.

Journal: Patient preference and adherence

Published: March 07, 2026

Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR: A Multicentre Cohort Study.

Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR: A Multicentre Cohort Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 10, 2026

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Journal: HIV medicine

Published: November 19, 2025

Use of long-acting cabotegravir and rilpivirine in people living with HIV: A prospective observational cohort study.

Use of long-acting cabotegravir and rilpivirine in people living with HIV: A prospective observational cohort study.

Journal: HIV medicine

Published: November 10, 2025

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Journal: Journal of the International AIDS Society

Published: October 11, 2025

Use of long-acting therapies for the HIV treatment in the Spanish pediatric cohort (CoRISpe).

Use of long-acting therapies for the HIV treatment in the Spanish pediatric cohort (CoRISpe).

Journal: Journal of infection and public health

Published: September 02, 2025

Exploratory Comparison of Meld, Meld-Na, and Meld 3.0 Scores for Prognostic Assessment at Diagnosis in Hepatocellular Carcinoma Using Machine Learning Approaches.

Exploratory Comparison of Meld, Meld-Na, and Meld 3.0 Scores for Prognostic Assessment at Diagnosis in Hepatocellular Carcinoma Using Machine Learning Approaches.

Journal: Digestive diseases and sciences

Published: August 06, 2025

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Journal: HIV medicine

Published: July 28, 2025

Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study.

Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: July 17, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026